AZITRA INC

CEO Salva Francisco’s bulk purchase of Azitra’s stock and preferred‑to‑common conversion signals strong insider confidence, prompting investors to watch upcoming clinical and cosmetic milestones for potential upside.

Azitra Inc. insider buying spurs optimism: COO Travis and executives exercise zero‑cost options, hinting at confidence in dermatology pipeline amid a low‑price stock.

CEO’s hefty purchase of Azitra’s Series A preferred stock & warrants shows strong confidence, but investors must weigh upside potential against dilution risk.